This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Health and Human Services Secretary Robert F. Kennedy Jr. will have to refrain f...
AstraZeneca and Handa Pharmaceuticals have agreed to pay a combined $51.4 millio...
The CDC officially axed Covid-19 shot recommendations for pregnant women from it...
Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytr...
Plus, news about Diakonos Oncology and Coherus: Roche’s longer-term data for...
What will the second half of 2025 bring for biopharma? It's a tough question...
It may not come as a surprise that one of the most unconventional US senators in...
Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the ri...
Sanofi and Regeneron on Friday reported lackluster late-stage results for their ...
→ Allyson McMillan-Youngblood has left Bristol Myers Squibb to join Acadia Pharm...
Summit Therapeutics’ PD-1xVEGF bispecific hit on progression-free survival in a ...
Astellas is the latest large pharmaceutical company to ink a deal with a Chinese...
The US Supreme Court will continue deciding whether to take up a pivotal case on...
As more healthcare startups pile on the longevity trend, I’ve noticed something ...
Eisai and Merck succeeded in stopping Shilpa Medicare Ltd. from launching a gene...
The first wave of biopharma comments on industry-specific tariffs is here. A...